|Articles|November 1, 2016
Schulman IRB to Launch COR Division
Schulman IRB will launch its new Central Oncology Review (COR) division this month.
Advertisement
Schulman IRB will launch its new Central Oncology Review (COR) division this month. The COR will feature a roster of oncology industry leaders, academics and distinguished scientists, each with a background in managing specialized oncology research.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
3
Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials
4
Accelerating Development Through Parallel Execution and Rigorous Quality Controls
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
